DK2022501T3 - Anvendelse af phytat som middel, der hæmmer opløsning af krystaller af calciumsalte, til forebyggelse og behandling af osteoporose - Google Patents

Anvendelse af phytat som middel, der hæmmer opløsning af krystaller af calciumsalte, til forebyggelse og behandling af osteoporose Download PDF

Info

Publication number
DK2022501T3
DK2022501T3 DK07765887T DK07765887T DK2022501T3 DK 2022501 T3 DK2022501 T3 DK 2022501T3 DK 07765887 T DK07765887 T DK 07765887T DK 07765887 T DK07765887 T DK 07765887T DK 2022501 T3 DK2022501 T3 DK 2022501T3
Authority
DK
Denmark
Prior art keywords
phytate
osteoporosis
inhibitor
prevention
treatment
Prior art date
Application number
DK07765887T
Other languages
English (en)
Inventor
Freixedas Felix Grases
Cortes Pilar Sanchis
Amengual Bernat Isern
Antonia Costa-Bauzá
Bestard Joan Perelló
Almirall Rafael Mará Prieto
González Ramón García
Original Assignee
Univ Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illes Balears filed Critical Univ Illes Balears
Application granted granted Critical
Publication of DK2022501T3 publication Critical patent/DK2022501T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK07765887T 2006-06-01 2007-05-30 Anvendelse af phytat som middel, der hæmmer opløsning af krystaller af calciumsalte, til forebyggelse og behandling af osteoporose DK2022501T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200601519A ES2288126B2 (es) 2006-06-01 2006-06-01 Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
PCT/ES2007/070102 WO2007138147A1 (es) 2006-06-01 2007-05-30 Utilización de fitato como agente inhibidor de la disolución de cristales de sales cálcicas para la prevención de la osteoporosis

Publications (1)

Publication Number Publication Date
DK2022501T3 true DK2022501T3 (da) 2019-11-04

Family

ID=38778157

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07765887T DK2022501T3 (da) 2006-06-01 2007-05-30 Anvendelse af phytat som middel, der hæmmer opløsning af krystaller af calciumsalte, til forebyggelse og behandling af osteoporose

Country Status (13)

Country Link
US (1) US8377909B2 (da)
EP (1) EP2022501B1 (da)
JP (1) JP2009538883A (da)
CN (2) CN103908455A (da)
AU (1) AU2007266983B2 (da)
CA (1) CA2654281C (da)
DK (1) DK2022501T3 (da)
ES (2) ES2288126B2 (da)
MX (1) MX2008015205A (da)
NO (1) NO344167B1 (da)
PL (1) PL2022501T3 (da)
PT (1) PT2022501T (da)
WO (1) WO2007138147A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2332636B1 (es) * 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
US9364490B2 (en) * 2013-03-15 2016-06-14 Laboratoris Sanifit, S.L. Use of derivatives containing C—O—P bonds in patients with kidney failure
US11028112B2 (en) 2015-12-11 2021-06-08 Eth Zurich Inositol derivatives for use in pathological crystallization
US11707470B2 (en) 2015-12-11 2023-07-25 Eth Zurich Inositol derivatives for use in pathological crystallization
KR102646016B1 (ko) * 2015-12-11 2024-03-08 에테하 쭈리히 병적인 결정화에서의 용도를 위한 이노시톨 유도체
DE102016013737A1 (de) 2016-11-17 2018-05-17 WindplusSonne GmbH Hexahydroxycyclohexanhexaphosphorsäureestersalze zur Behandlung von Kalzinose sowie diätische Lebensmittel mit Hexahydroxycyclohexanhexaphosphorsäureestersalzen als Zusatzstoffe
EP3701952A4 (en) * 2017-10-26 2021-06-30 Otsuka Pharmaceutical Co., Ltd. INOSITE PHOSPHATE COMPOSITION
AU2018445164A1 (en) 2018-10-11 2021-04-22 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
WO2020157362A1 (en) 2019-01-30 2020-08-06 Sanifit Therapeutics, S.A. Inositol phosphate compounds for use in increasing tissular perfusion
EP3818983A1 (en) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
EP4036097A1 (en) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6 substituted derivative compounds
WO2024023360A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip5 substituted compounds
WO2024023359A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015634A (en) 1986-04-16 1991-05-14 Perstorp Ab Method of treating tissue damage with inositol triphosphate
US5057507A (en) 1986-04-16 1991-10-15 Perstorp Ab Method of alleviating bone damage with inositoltriphosphate
SE8904355D0 (sv) 1989-12-21 1989-12-21 Perstorp Ab Medicament
JP3320359B2 (ja) * 1998-06-09 2002-09-03 太子食品工業株式会社 有機態亜鉛を添加した食品
ES2152899B1 (es) 1999-07-16 2002-03-16 Univ Illes Balears Aplicacion de harinas de germen de ciertos cereales en la fabricacion de productos alimenticios utiles para el tratamiento de estados carenciales en fitatos.
CN1120725C (zh) 1999-11-12 2003-09-10 高同祥 治疗骨质疏松、增生的药物及其制备方法
US7968342B2 (en) * 2002-08-12 2011-06-28 Danisco Us Inc. Mutant E. coli appa phytase enzymes and natural variants thereof, nucleic acids encoding such phytase enzymes, vectors and host cells incorporating same and methods of making and using same
JP4595080B2 (ja) * 2003-09-25 2010-12-08 学校法人明治大学 セメント用材料およびセメント
ES2232302B1 (es) * 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
GB0517466D0 (en) * 2005-08-26 2005-10-05 Immunodiagnostic Systems Plc Diagnostic assay and therapeutic treatment
US20070212449A1 (en) * 2006-03-02 2007-09-13 Shamsuddin Abulkalam M Reduction of the titratable acidity and the prevention of tooth and other bone degeneration
JP2007302600A (ja) * 2006-05-11 2007-11-22 Kaneka Corp イネ属植物材料由来の骨代謝改善用組成物とその製造方法

Also Published As

Publication number Publication date
PL2022501T3 (pl) 2020-03-31
AU2007266983A1 (en) 2007-12-06
CA2654281C (en) 2013-12-24
EP2022501A1 (en) 2009-02-11
CN103908455A (zh) 2014-07-09
MX2008015205A (es) 2009-03-12
EP2022501B1 (en) 2019-08-14
WO2007138147A1 (es) 2007-12-06
ES2748108T3 (es) 2020-03-13
PT2022501T (pt) 2019-11-06
ES2288126A1 (es) 2007-12-16
CA2654281A1 (en) 2007-12-06
ES2288126B2 (es) 2009-07-06
US20090203650A1 (en) 2009-08-13
CN101484174A (zh) 2009-07-15
NO344167B1 (no) 2019-09-23
BRPI0711506A2 (pt) 2011-11-01
NO20085374L (no) 2009-03-02
US8377909B2 (en) 2013-02-19
AU2007266983B2 (en) 2011-10-13
EP2022501A4 (en) 2009-11-11
JP2009538883A (ja) 2009-11-12

Similar Documents

Publication Publication Date Title
DK2022501T3 (da) Anvendelse af phytat som middel, der hæmmer opløsning af krystaller af calciumsalte, til forebyggelse og behandling af osteoporose
DK1942898T4 (da) Dipeptidylpeptidase-inhibitorer til behandling af diabetes
DK2439205T3 (da) Carboxamidforbindelser og deres anvendelse som calpaininhibitorer
DK1945631T3 (da) 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
DK1756084T3 (da) Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed
DK2040713T3 (da) Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
DK2177224T3 (da) Forbindelse til forebyggelse og behandling af lidelser, som involverer modulation af RyR-receptorerne
DK2139892T3 (da) Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer
DK1732562T3 (da) Substituerede pyridinyl- og pyrimidinylderivater som modulatorer af metabolisme og behandling af forstyrrelser relateret dertil
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
DK1586319T3 (da) Thiadiazolidinoner som GSK-3-inhibitorer
ATE550329T1 (de) Heterobicyclische sulfonamidderivate zur behandlung von diabetes
DK2099447T3 (da) Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
DK2383271T3 (da) Aminoquinoloner som GSK-3-inhibitorer
DK2120932T3 (da) Indazolderivater som kinasehæmmere til behandling af kræft
DK1981875T3 (da) Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase
DK2121614T3 (da) Aminonikotin og isonikotinsyrederivater som dhodh-inhibitorer
ZA200807234B (en) GSK-3 inhibitors for the treatment of osteoporosis
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
CL2007002972A1 (es) Compuestos derivados de imidazolona e imidazolidinona, inhibidores de la 11b-hsd1; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para el tratamiento y prevencion de diabetes, obesidad, trastornos alimentarios, disl
IL199103A0 (en) Non-nucleoside reverse transcriptase inhibitors
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
BRPI0817096A2 (pt) análogos de tiazolidinodiona para o tratamento de hipertensão
DK2010496T3 (da) 4-anilinoquinolin-3-carbonsyreamider som CSF-1R-kinaseinhibitorer
DK1954690T3 (da) Benzamidforbindelser, der er anvendelige som inhibitorer af histondeacetylase